Australian cancer patients will soon be able to test a potentially "game-changing" melanoma treatment that could extend their lives for years.
A large trial combining two drugs for people with advanced melanoma is due to begin at several Australian hospitals in coming months after a small American study of 52 people found the treatment shrank most participants’ tumours. The clinical trial by the Ludwig Centre at Memorial Sloan-Kettering Cancer Centre found that while nine out of 10 patients responded to the treatment, 16 or one-third of the patients’ tumours regressed more than 80 per cent and five of these patients’ tumours regressed completely.
